Skip to main content
TipRanks
Go Ultimate75% OFF

Novo Integrated Sciences (NVOS) AI Stock Analysis

245 Followers
NVOS

Novo Integrated Sciences

(Other OTC:NVOS)

Select Model
Rating:37Underperform
Price Target:$0.00â–¼(-100.00% Downside)
Action:initiatedcoverage
Date:07/23/25

The overall score is driven by extraordinarily weak financial performance and valuation: persistent operating and net losses, worsening negative cash flow, and no dividend or earnings support the lowest possible assessment. Technical analysis is also scored at the minimum due to the lack of positive indicators and a very low share price, reflecting high investor caution and likely negative sentiment. With no offsetting positives or external events, the score reflects acute risk and minimal investor confidence.

Positive Factors
Revenue GrowthConsistent revenue growth indicates expanding market reach and product adoption, which can support long-term business sustainability.
Negative Factors
Negative Profit MarginsNegative profit margins indicate operational inefficiencies and high costs, which can hinder profitability and long-term financial health.

Novo Integrated Sciences (NVOS) vs. SPDR S&P 500 ETF (SPY)

-40%-30%-20%-10%0%10%20%NVOS-33.33%SPY+11.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$17.76K
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
0.0
Beta (1Y)
3.55
Revenue Growth
―
EPS Growth
―
Country
US
Employees
115
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Novo Integrated Sciences Business Overview & Revenue Model

Company Description

Novo Integrated Sciences, Inc. (NVOS) delivers a diverse array of primary healthcare services and related products through its two primary operational segments: Healthcare Services and Product Manufacturing and Development. The company's extensive se...

How the Company Makes Money

Novo Integrated Sciences generates revenue through several key streams, including the sale of its proprietary health and wellness products, licensing agreements for its technology and products, and partnerships with healthcare providers and distribut...

Novo Integrated Sciences Financial Statement Overview

Summary

Novo Integrated Sciences demonstrates severe financial weakness: persistent operating and net losses (net margin at -121.3%, EBIT and EBITDA at -75.8%), worsening negative free cash flow (-$2.3M with no year-over-year improvement), and a deteriorating equity base. While revenue grew modestly and leverage is only moderately high, these positives are overshadowed by chronic unprofitability and cash burn, raising major concerns about sustainability.

Income Statement

18Very Negative

Balance Sheet

25Negative

Cash Flow

11Very Negative
Financial statement breakdown
BreakdownTTMAug 2024Nov 2023Feb 2023Nov 2021Aug 2020
Income Statement
Total Revenue13.29M13.29M12.57M11.74M9.31M7.86M
Gross Profit5.74M5.74M4.95M4.80M3.82M3.06M
EBITDA-6.64M-14.52M-5.85M-22.48M-2.58M-3.32M
Net Income-16.17M-16.13M-13.21M-32.85M-4.46M-4.92M
Balance Sheet
Total Assets32.14M32.14M35.56M40.87M61.96M35.39M
Cash, Cash Equivalents and Short-Term Investments844.58K844.58K416.32K2.18M8.29M2.07M
Total Debt4.71M4.71M4.47M13.00M13.71M4.39M
Total Liabilities17.53M17.53M11.06M18.83M18.15M5.82M
Stockholders Equity14.89M14.89M24.82M22.31M43.86M29.62M
Cash Flow
Free Cash Flow-5.07M-2.29M-2.29M-6.07M-1.28M-453.80K
Operating Cash Flow-5.07M-2.24M-2.24M-5.88M-1.02M-441.69K
Investing Cash Flow-5,033-49.22K-49.22K163.46K3.00M657.13K
Financing Cash Flow4.99M763.86K763.86K-427.12K4.32M-271.69K

Novo Integrated Sciences Risk Analysis

Novo Integrated Sciences disclosed 16 risk factors in its most recent earnings report. Novo Integrated Sciences reported the most risks in the "Ability to Sell" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Ability to Sell - Risks related to the company’s ability to sell goods and services

Latest Risks Added

0 New Risks

Novo Integrated Sciences Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

NVOS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CCELCCEL53Neutral$33.62M-18.6015.84%―-1.96%-314.41%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AMSAMS50Neutral$6.88M-3.03-10.19%―4.90%-3.41%
PIIIPIII48Neutral$15.61M-0.09171.75%―7.54%42.43%
MNDRMNDR43Neutral$1.13M-0.04-27.32%―4.47%92.03%
CCMCCM40Underperform$15.67M-0.035.16%―20.26%69.68%
NVOSNVOS37Underperform$17.76K0.00-81.23%―――

* Healthcare Sector Average

Performance Comparison

0%100%NVOSAMSCCMCCELPIIIMNDRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
NVOS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NVOSNovo Integrated Sciences, Inc.0.02-0.01-33.33%
AMSAmerican Shared Hospital Services1.03-1.04-50.24%
CCMConcord Medical Services3.610.010.28%
CCELCryo-Cell International 4.170.081.91%
PIIIP3 Health Partners Inc.2.15-3.56-62.35%
MNDRMobile-health Network Solutions Class A0.95-27.55-96.67%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jul 23, 2025